Zileuton
Structural formula | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1: 1 mixture of ( R ) -form (top) and ( S ) -form (bottom) | |||||||||||||||||||
General | |||||||||||||||||||
Non-proprietary name | Zileuton | ||||||||||||||||||
other names |
|
||||||||||||||||||
Molecular formula | C 11 H 12 N 2 O 2 S | ||||||||||||||||||
External identifiers / databases | |||||||||||||||||||
|
|||||||||||||||||||
Drug information | |||||||||||||||||||
Drug class |
Lipoxygenase inhibitor |
||||||||||||||||||
properties | |||||||||||||||||||
Molar mass | 236.29 g · mol -1 | ||||||||||||||||||
Physical state |
firmly |
||||||||||||||||||
Melting point |
157-158 ° C |
||||||||||||||||||
safety instructions | |||||||||||||||||||
|
|||||||||||||||||||
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . |
Zileuton is a 5-lipoxygenase inhibitor . It acts selectively and reversibly on 5-lipoxygenase , which produces leukotrienes LTA 4 , LTB 4 , LTC 4 , LTD 4 and LTE 4 released in the event of inflammation .
Zileuton is used in the USA as a medicinal substance for mild to moderate bronchial asthma . An effect is also expected against other inflammatory diseases, but this is still to be proven by studies.
In Germany there are no approved finished medicinal products with this active ingredient.
Individual evidence
- ^ The Merck Index : An Encyclopedia of Chemicals, Drugs, and Biologicals , 14th Edition (Merck & Co., Inc.), Whitehouse Station, NJ, USA, 2006; P. 1746, ISBN 978-0-911910-00-1 .
- ↑ harmonized classification for this substance . A labeling of (RS) -N- [1- (1-benzothien-2-yl) ethyl] -N-hydroxyurea in the Classification and Labeling Inventory of the European Chemicals Agency (ECHA), retrieved on December 12, is reproduced from a self-classification by the distributor July 2020. There is not yet a
- ↑ ABDA database (as of June 18, 2008) of DIMDI .